Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipatasertib + docetaxel
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ipatasertib + docetaxel is a combination therapy consisting of **ipatasertib**, an oral, selective, ATP-competitive inhibitor of **AKT (protein kinase B)**, and **docetaxel**, an intravenous chemotherapeutic agent classified as a taxane that acts as a microtubule inhibitor. Ipatasertib targets the PI3K/AKT signaling pathway, which is frequently dysregulated in human cancers, especially those with PTEN loss, leading to unregulated cell proliferation and survival. Docetaxel stabilizes microtubules and inhibits their depolymerization, disrupting cell division. The combination aims to leverage potential synergy, as AKT inhibition can sensitize tumor cells to chemotherapy. Clinical trials are evaluating this combination primarily in advanced solid tumors, metastatic non-small cell lung cancer (NSCLC), and metastatic castration-resistant prostate cancer (mCRPC)[1][2][5].
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ipatasertib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipatasertib + docetaxel.